Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The ...
1don MSN
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Nova 2.0 has been kicked into the reeds after nutritionists kicked up a stink, but Novo Nordisk seems adamant to develop a ...
TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up ...
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...
E! Online on MSN1d
Why Nikki Glaser Is Fiercely Defending OzempicGolden Globes host Nikki Glaser shared why she supports people using the injectable drug Ozempic for weight loss, and also ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Zacks.com on MSN1d
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback